Rapastinel

DRUG13 trials

Sponsors

Naurex, Inc, an affiliate of Allergan plc

Conditions

Depressive Disorder, MajorDriving PerformanceHuman Abuse Potential

Phase 1

Assessment of Abuse Potential of Rapastinel in Humans

CompletedNCT03799900

Naurex, Inc, an affiliate of Allergan plcHuman Abuse Potential

Start: 2018-11-01End: 2019-03-29Updated: 2019-05-16

Assessment of Effect of Rapastinel on Driving Performance

CompletedNCT03814733

Naurex, Inc, an affiliate of Allergan plcDriving Performance

Start: 2018-11-05End: 2019-04-03Updated: 2019-07-11

Phase 2

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

TerminatedNCT03352453

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2017-12-15End: 2019-06-21Updated: 2020-08-14

Phase 3

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

CompletedNCT02932943

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2016-10-15End: 2018-11-08Updated: 2019-10-11

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

CompletedNCT02943577

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2016-11-02End: 2018-11-21Updated: 2019-11-13

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

CompletedNCT02943564

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2016-11-01End: 2018-12-18Updated: 2019-12-27

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

CompletedNCT02951988

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2016-11-13End: 2019-02-22Updated: 2020-03-09

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

CompletedNCT03002077

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2017-02-03End: 2018-12-06Updated: 2020-06-22

Study of Rapastinel as Monotherapy in Patients With MDD

TerminatedNCT03560518

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2018-06-15End: 2019-07-08Updated: 2020-09-01

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

TerminatedNCT03614156

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2018-08-02End: 2019-07-11Updated: 2020-10-09

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

TerminatedNCT03668600

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2018-08-23End: 2019-07-03Updated: 2020-07-17

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

TerminatedNCT03675776

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2018-10-30End: 2019-07-11Updated: 2020-07-28

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

WithdrawnNCT03855865

Naurex, Inc, an affiliate of Allergan plcDepressive Disorder, Major

Start: 2019-07-01End: 2020-12-31Updated: 2019-07-19